Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by two main pathological hallmarks; amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Although, amyloid beta may play a causative role in AD progression, tau pathology {1} and synaptic loss {2} better correlate with cognitive performance. For this study, the authors focused on tau-P301S (P301S) mice, which overexpress a mutant form of human tau. Working predominantly with 9-month-old mice, the authors found that there is clear tau pathology and synaptic dysfunction but not gross hippocampal degeneration. Total tau levels between transgenic and non-transgenic animals were unchanged at both a lysate and post-synaptic density (PSD) level, but certain epitopes of phosphorylated tau were strongly enriched in P301S. Interestingly, the enrichment of tau phosphoepitopes differed between the PSD and lysate (i.e. phosphorylation of Ser404 was elevated in lysate compared to PSD while phosphorylation of Thr231 was elevated in PSD compared to lysate), suggesting a relationship between aberrant localization and specific phosphorylation events. In order to understand the effects of this aberrant tau aggregation, the authors performed label-free quantitative mass spectrometry (MS) on hippocampal PSDs from P301S and non-transgenic mice. They identified 1257 unique proteins, 76 were significantly increased and 45 significantly decreased in P301S mice at 9 months of age (n=3 P301S, 3 Cntrl). Gene ontology analysis revealed down-regulation of processes related to synaptic structure and activity in contrast to up-regulation of pathways related to translation and biosynthesis. Furthermore, the authors found a significant enrichment of AD-associated proteins among the proteins decreased in P301S PSDs; however, the amyloid precursor protein (APP) was significantly enriched in P301S PSDs, suggesting there may be a relationship between tau pathology and amyloid alterations. As a validation of these results, knockdown of some of the proteins identified in this screen was capable of reducing spine density in a hippocampal cultures. The full quantitative MS data are available through this paper as a useful resource. One of the most significantly altered proteins identified in the MS screen was C1q. Dejanovic et al. found that C1q was enriched in total lysates but was even further enriched in PSDs from P301S mice compared to wild type. Utilizing super resolution microscopy as well as correlative light-electron microscopy (CLEM), the authors were able to show increased co-localization between C1q and post-synaptic membranes in P301S. There was strong positive correlation between C1q levels and AT8, a marker of fibrillated tau, staining. The co-accumulation of tau pathology and C1q appeared to be specific to excitatory synapses as PSD-95 but not gephyrin co-immunoprecipitated with both modified human tau and C1q. However, C1q accumulation in the hippocampus lagged behind AT8 staining, only rising above wild-type animals at 9 months of age whereas AT8 staining was evident by 6 months. The authors next turned to human samples to analyze changes in C1q in relation to AD specifically. They found that C1q levels were elevated in the superior frontal gyrus (SFG) ~1.5-fold in "early-stage" AD and ~2-fold in autopsy confirmed AD. At the synaptic level, C1q was also elevated in both early and confirmed AD. Transcript level data from the fusiform gyrus also showed an increase in the complement cascade in confirmed AD patients. These data support a connection between AD pathology and C1q accumulation that warrants further investigation. Given the hypothesis that C1q triggers microglial engulfment and pruning of synapses {3}, Dejanovic et al. examined the relationship between C1q accumulation and microglial engulfment of synapses in P301S mice. They found that at 6 months of age, where there is little rise in C1q, that there was no change in synaptic density or co-localization of microglial lysosomes and synaptic markers. In contrast, at 9 months of age they found elevated levels of C1q, decreased synaptic density, and an increase in co-localization between synaptic and microglial markers, supporting the hypothesis that C1q may drive microglial elimination of synapses. To test this hypothesis the authors utilized a C1q blocking antibody. In vitro the authors found that this antibody was able to prevent the loss of microglia-proximal dendrites in hippocampal rat cultures expressing P301S tau. Next, the authors compared the effects of the anti-C1q antibody in vivo, using P301S mice. They found that 5 days after injection into the dorsal hippocampus of 9-month-old mice, there was a 50% reduction in co-localization between PSD-95 and microglial lysosomes, suggesting that the anti-C1q injection was able to prevent microglial engulfment of synapses. However, at this time point, in slices, electrophysiological changes were not detected. Overall, this paper provides strong supporting evidence that alterations in tau are capable of driving changes in the synaptic proteome and ultimately synaptic loss. Evidence from this paper supports the hypothesis that C1q elevation in neurodegenerative disease may cause microglial engulfment and elimination of spines. The pathways identified in this paper suggest novel drug targets not only for AD but also for tauopathies in general.